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Abstract 
Two new Pd(II) complexes have been prepared from 2-methyl 4-amino quinoline and 
[PdCl2(EPh3)2] (E = P or As). The complexes, [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] were 
characterized by elemental analysis, NMR, IR and UV-Vis absorption spectroscopy and single 
crystal X-ray diffraction. The binding affinity and the binding mode of the ligand and the 
complexes toward CT-DNA/BSA were determined by spectrophotometric titrations and strong 
interaction of the complexes with CT-DNA and BSA has been observed. An in vitro cytotoxicity 
study of the compounds against human lung (A-549) and breast (MCF-7) cancer cell lines gave 
IC50 values for both the ligand and the two complexes in the range of Cisplatin and Doxorubicin. 
Keywords: Quinoline; Pd(II) complexes; DNA/protein binding; Cytotoxicity. 
Introduction 
Currently, one of the most important areas of research in bioinorganic chemistry is the design 
and synthesis of transition metal complexes as efficient anticancer agents [1–5]. In this 
connection, Pd(II) complexes have attracted the attention of bioinorganic chemists as potential 
alternative to cisplatin that is being currently administered because of the fact that the Pd(II) 
complexes can undergo aquation and ligand exchange reactions 105 times faster than the 
corresponding Pt(II) complexes. Hence, a new area of active research in bioinorganic chemistry 
has emerged recently targeting new drugs of cancer cell specific [6-8] and  a number of Pd(II) 
complexes [9-15] have even shown better anticancer properties that that of Pt(II) complexes due 
to the structural and thermodynamic similarities between Pd(II) and  Pt(II) complexes. 
As far as the ligands used for the synthesis of new Pd(II) complexes is concerned, 
quinolines are best suited since they are  a class of compound that has been used in agriculture as 
fungicide besides being used as preservatives in wood, paper and textile industries [16]. In this 
connection, it is to be noted that alkaloid and alkaloid based compounds contain quinoline as an 
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important structural unit which exhibited substantial biological activities [17,18]. Moreover, the 
biological activities such as antioxidation, antiproliferation and anticancer have also been 
exhibited by the derivatives of quinolones [19-22]. This has really created a special interest in the 
synthesis of transition metal complexes of quinolines and to study their role in inhibiting cancer 
cell proliferation and microbial growth [23-26]. The results have indicated that the complexes 
thus prepared have not only shown significant pharmacological properties but also revealed 
interesting coordination modes of quinolines in the complexes. Hence, we synthesized two new 
Pd(II) complexes from aquinoline derivative. Interestingly, the complexes contain the ligand 
coordinated through the quinoline pyridine nitrogen atom only. Herein, we report the synthesis, 
structures, DNA interactions, protein binding, molecular docking and cytotoxicity studies of 
mononuclear palladium complexes of 2-methyl 4-amino quinoline.  
Results and discussion 
Synthesis  
The preparative route for the new complexes [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] is shown 
in Scheme 1. The new complexes were prepared by the reaction of the 2-methyl 4-amino 
quinoline with [PdCl2(PPh3)2] or [PdCl2(AsPh3)2] in toluene. They were obtained in good yields 
and characterized by IR, UV-visible, fluorescence spectroscopy, 1H NMR and single crystal X-
ray diffraction methods. Both the ligand and complexes are air stable. They are soluble in 
methanol, ethanol and methylene dichloride, trichloromethane, dimethylformamide and 
dimethylsulfoxide. 
 
Scheme 1. Preparation route of the Pd(II) complexes. 
Spectroscopy 
Electronic spectra of the complexes showed two strong absorption bands, one in the regions at 260-
264 corresponding to intra ligand transition and the other at 315-328 nm which has been assigned to 
ligand to metal charge transfer transition [27]. The IR spectra of the complexes [PdCl2(L)(PPh3)] 
and [PdCl2(L)(AsPh3)] displayed characteristic absorption bands in the regions 3373-3391 and 
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1356-1359cm-1 due to (-NH2) and (-CH3) vibrations respectively. The aromatic (C=N) frequency 
for the free ligand which appeared at 1610-1614 has been shifted to 1642-1638 cm-1 for the 
complexes 1 and 2 indicating that the palladium ion is coordinated to the nitrogen atom. The1H 
NMR spectra of the complexes are shown in Figures S1 & S2. The signal due to –NH2 proton 
was observed as doublets at δ 8.14-8.17 and 9.48-9.50 ppm in the spectra of [PdCl2(L)(PPh3)] 
and [PdCl2(L)(AsPh3)]. Two singlets appeared at δ 2.89 and 2.97 ppm for methylene protons in 
the complexes. Further the spectra of the two complexes showed a series of overlapping 
multiplets for aromatic protons at δ 7.30-7.89 and 6.73-7.43 ppm respectively.  
Crystallography 
Complex [PdCl2(L)(PPh3)] consists of a distorted square planer Pd(II) metal center coordinated 
to two cis chloride ligands, a PPh3 group and a quinoline which was attached in a neutral manner 
through the pyridyl N  as shown Figure1.  The compound crystallized in the monoclinic space 
group P21/c with two unique molecules in the asymmetric unit (Z’=2) with two molecules in the 
asymmetric unit. Intermolecular π-π interactions were identified between pairs of quinolone rings 
between one of the phenyl rings and the quinolone Table 1 and Figure2.  Intermolecular N-
H···Cl hydrogen bonding was also identified (Table S1).The crystal structure of complex 
[PdCl2(L)(AsPh3)]  was obtained as a solvate with methanol with a distorted square planar Pd(II) 
metal center coordinated to two cis chloride ligands, a AsPh3 group and a quinoline which was 
attached in a neutral manner through the pyridyl N shown in Figure 3. This complex crystallized 
in the monoclinic space group P21/n with one molecule of [PdCl2(L)(AsPh3)]  in the asymmetric 
unit along with methanol. Intermolecular hydrogen bondings O-H···Cl, N-H···O and N-H···Cl 
were identified but no π-π interactions were seen in this case (Table 1). The data collection and 
parameters of refinement progression are given in Table 3 and important bond lengths and bond 
angles are summarized in Table 4. 
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Figure 1. Molecular structure of complex 1. 
 
Figure 2. Molecular structure of Intermolecular π-π interactions in complex [PdCl2(L)(PPh3)]  
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Figure 3. Molecular structure of complex [PdCl2(L)(AsPh3)]. 
Table 1. π-π interactions in complex [PdCl2(L)(PPh3)]  
Ring 1 Ring 2 Centroid-centroid (Å) Shift (Å) 
Complex 1    
C1-C6 C22-C27
i 
3.539 1.017 
C1-C6 N1, C19-C23
i 
3.416 1.556 
C22-C27 N3, C47-C51
ii 
3.619 1.487 
N1, C19-C23 C50-C55ii 3.686 1.746 
N1, C19-C23 N3, C47-C51ii 3.831 2.045 
C29-C34 C50-C55i 3.644 1.279 
C29-C34 N3, C47-C51
i 
3.354 1.308 
i +x, +y, +z; ii 1+x, +y, +z 
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Table 3. Crystal structure data for the complex [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)]. 
Identification code [PdCl2(L)(PPh3)]   [PdCl2(L)(AsPh3)] 
CCDC number 1498615 1498616 
Empirical formula  C28H25Cl2N2PPd  C28.8H28.2AsCl2N2O0.8Pd 
Formula weight  597.77  667.35 
Temperature/K  100(2)  100(2) 
Crystal system  monoclinic  Monoclinic 
Space group  P21/c P21/n 
a/Å  10.2603(5)  10.7382(2) 
b/Å  28.1702(14)  17.4602(2) 
c/Å  17.1676(8)  14.5297(2) 
α/°  90  90 
β/°  90.614(3)  105.2002(7) 
γ/°  90  90 
Volume/Å3 4961.7(4)  2628.89(7) 
Z  8  4 
ρcalcg/cm3 1.600  1.686 
μ/mm-1 1.048  2.183 
F(000)  2416.0  1338.0 
Crystal size/mm3 0.39 × 0.28 × 0.21  0.47 × 0.28 × 0.24 
Radiation  MoKα (λ = 0.71073)  MoKα (λ = 0.71073) 
2Θ range for data collection/°  2.778 to 55.78  3.726 to 55.906 
Index ranges  
-13 ≤ h ≤ 13, -28 ≤ k ≤ 
37,  
-22 ≤ l ≤ 22  
-14 ≤ h ≤ 10, -23 ≤ k ≤ 
21,  
-19 ≤ l ≤ 19 
Reflections collected  44782  23594 
Rint 0.0389 0.0270 
Data/restraints/parameters  11812/0/631 6306/13/336 
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Goodness-of-fit on F2 1.081 1.048 
Final R indexes [I>=2σ (I)]  
R1 = 0.0408, wR2 = 
0.0825 
R1 = 0.0270, wR2 = 
0.0608 
Final R indexes [all data] 
R1 = 0.0561, wR2 = 
0.0889 
R1 = 0.0351, wR2 = 
0.0640 
Largest diff. peak/hole / e Å-3 1.27/-0.72 1.16/-0.85 
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Table 4. Particular bond lengths (Å) and bond angles (˚) in the complexes 
Bond length (Å) 
[PdCl2(L)(PPh3)] 
Bond length (Å) 
[PdCl2(L)(AsPh3)] 
Pd1-Cl1-2.3789(8)   
Pd1-Cl2-2.3092(8) 
Pd1-P1-2.2571(8) 
Pd1-N1-2.047(3) 
N1-C19-1.346(4) 
N1-C23-1.373(4)  
Bond angle (˚) 
Cl2-Pd1-Cl1-91.37(3) 
P1-Pd1-Cl1-179.41(3)   
P1-Pd1-Cl2-89.20(3) 
N1-Pd1-Cl1-89.77(7) 
N1-Pd1-Cl2-177.30(8)                         
N1-Pd1-P1-89.67(7)                            
C1-P1-Pd1-114.44(10) 
C7-P1-Pd1-115.20(10)   
C13-P1-Pd1-114.09(11)  
C2-N1-Pd1-121.68(16) 
Pd1-As1-2.3506(3) 
Pd1-Cl2-2.2945(6) 
Pd1-Cl1-2.3411(7) 
Pd1-N1-2.040(2) 
Bond angle (˚) 
Cl2-Pd1-As1-88.849(17) 
Cl2-Pd1-Cl1-91.51(3) 
Cl1-Pd1-As1-178.71(3) 
N1-Pd1-As1-92.14(5) 
N1-Pd1-Cl2-176.72(6) 
N1-Pd1-Cl1-87.57(6) 
Cl1-As1-Pd1-113.83(7) 
C23-As1-Pd1-113.59(7) 
C23-As1-Cl1-103.95(10) 
C17-As1-Pd1-115.38(7) 
C6-N1-Pd1-118.65(16) 
 
 
DNA binding studies 
DNA binding of the ligand and the new compounds was carried out as it is considered one of the 
important aspects in deciding whether a compound could be an anticancer drug [28,29]. 
Electronic absorption titration is the effective method to test the binding modes of compounds 
with DNA [30]. The spectral features will be seen in terms of hyperchromism and 
hypochromism concerned with modifications of DAN double helix structure. The interaction of 
the compounds with CT-DNA was followed by recording the UV-visible spectra by the 
increased addition of the CT-DNA to the test compounds (Figure 4). When the ligand was 
titrated against CT-DNA, the absorption bands of the ligand exhibited hyperchromism with a red 
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shift of4 nm. In the case of the complex[PdCl2(L)(PPh3)], on the addition of DNA, it exhibited 
hyperchromism with a red shift of 4 nm and complex [PdCl2(L)(AsPh3)] exhibited 
hyperchromism without any wavelength shift. Complex [PdCl2(L)(PPh3)] showed more 
hyperchromicity than that of the ligand and complex [PdCl2(L)(AsPh3)]  indicating more binding 
strength for the complex [PdCl2(L)(PPh3)]. From the plot of [DNA]/(εa-εf) versus [DNA] (Figure 5), 
the intrinsic binding constants Kb were calculated and they were found to be 0.342 × 10
6, 1.6528 × 
106 and 0.5660 × 105 M-1 for the ligand and the complexes [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] 
respectively indicating that the ligand and the complexes bind to DNA via an intercalative mode 
[31]. 
 
 
Figure 4. Absorbtion titration of the compounds in the absence and presence of CT-DNA. Ligand 
(A), complex[PdCl2(L)(PPh3)] (B), and complex [PdCl2(L)(AsPh3)] (C). [Compounds] = 10 µM, 
[DNA] = 0-100 µM. Arrow indicatesthat the absorption intensities increase upon incremental 
concentration of DNA. 
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Figure 5. Plot of [DNA]/(εa-εf) versus [DNA]. 
Ethidiumbromide(EB) displacement study  
Though the electronic absorption studies indicate that the compounds efficiently bind to DNA,  it 
is not enough to conclusively say that there exists a binding and hence, there is a need to prove 
this by other studies. In this connection, ethidiumbromide(EB) displacement experiments are 
considered to be the best technique to confirm the binding mode. Since EB forms soluble 
compounds with nucleic acids and emits intense fluorescence in the presence of CT-DNA due to 
the intercalation of the planar phenanthridine ring between adjacent base pairs on the double 
helix [32], one can obtain information on the binding mode of any compound with DNA. In the 
EB displacement study, there is a decrease in the intensity of fluorescence as and when  EB is 
displaced  from a DNA sequence by a quencher and the quenching will be due to the reduction of 
the number of binding sites on the DNA that is available to EB. Figure S3 shows the 
fluorescence quenching spectra of DNA bound EB by compounds and illustrate that as the 
concentration of the compounds increases the emission band at 626 nm showed hypochromism. 
The observed decrease in the fluorescence intensity indicates that the EB molecules have been 
displaced from their DNA binding sites and are replaced by the test compounds [33,34]. The 
quenching constants and binding constants can be analyzed through a couple of equations. The 
following Stern-Volmer equation is used obtain the quenching constant, 
I0/I = Kq[Q] + 1 
Where I0 and I represent the emission intensities in the absence and presence of the complexes, 
respectively, Kq is the quenching constant, and [Q] is the concentration ratio of the complex. 
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From the slope of  the plot of I0/I versus [Q],  one can  obtain Kq values (Figure S4) and the 
values obtained for the ligand and complexes were found to be  2.61 × 103, 4.16 × 103 and3.53 × 
103 M-1. These values do indicate that the ligand and Pd(II) complexes interact with DNA 
through  intercalation mode of binding  [35]. 
Protein binding studies 
In order to find out the interaction of the compounds with protein, we undertook the study of 
interaction of our compounds with BSA.  A constant concentration of BSA (1 µM) was titrated with 
various concentrations of the compounds (0–100 µM) and the fluorescence emission spectra were 
recorded (Figure S5). It can be seen that the effect of compounds on BSA resulted in a significant 
decrease in the fluorescence intensity at 347 nm with no shift in their emission wavelength 
maxima. The observed decrease in the fluorescence intensity could be attributed to the fact that the 
active site in the protein is buried in a hydrophobic environment [36,37]. By using the following 
Scatchard equation, the fluorescence quenching data can be analyzed. 
log[F0-F/F ] = log Kbin+ n log[ Q] 
Where Kbin is the binding constant of the compound with BSA and n is the number of binding sites. 
The binding constants Kbin have been calculated from the plot of log[F0-F/F ] versus log[Q] as shown 
in (Figure S6-A). Further, from the Stern-Volmer the plot of I0/I versus [Q], the quenching constants 
Kq have been calculated (Figure S6-B). The values of Kq, Kbin, and n, the number of binding site are 
given in table 5 and the value of n around 1 for the ligand and complexes indicates the existence of 
just a single binding site in BSA with the compounds. It is to be noted here that the complex 
[PdCl2(L)(PPh3)] has better binding affinity than that of the ligand and complex [PdCl2(L)(AsPh3)]. 
Table 5. Quenching constant (Kq), binding constant (Kbin), and number of binding sites (n) 
for the interactions of compounds with BSA.  
 
 
 
 
UV absorption spectra of BSA in the presence of compounds 
After having found out binding constants and the quenching constants for the compounds under 
study, it is necessary to know about type of quenching in order to get more insight which can be 
Compound            Kq (M
-1)        Kbin(M
-1)      n 
Ligand                   3.02 × 103     5.43 × 102     0.81 
[PdCl2(L)(PPh3)]  9.60 × 10
2     4.08 × 104     0.93 
[PdCl2(L)(AsPh3)] 3.88 × 10
3      2.77 × 102    0.76 
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obtained through absorption spectroscopy. Quenching usually occurs through two proesses 
namely,  dynamic or static quenching. If the fluorophore and the quencher come into contact 
during the transient existence of the excited state, it is referred to asdynamic quenching and if the 
same takes place in ground state then it is referred tostatic quenching. The UV absorption spectra 
of BSA taken in the presence and absence of the compounds under study are shown in Figure 10. 
The absorption intensity has increased on the addition of the compounds which indicates a static 
quenching of the compounds with BSA [38]. 
 
Figure 10. Absorbance titration of BSA with the ligand and complexes. 
Synchronous fluorescence spectra 
In addition to the studies conducted as above, synchronous fluorescence spectral studies have 
also been employed to observe the structural changes occurred to BSA upon the addition of 
compounds, particularly in the vicinity of the fluorophore functional groups [39]. It is known that 
fluorescence of BSA is due to the presence of tyrosine, tryptophan and phenylalanine residues 
and hence, fluorescence spectroscopic methods can be effectively used to study the conformation 
of serum protein. In this connection, it has been shown that the difference between the excitation 
wave length and emission wavelength (∆λ = λem - λex) will indicate the type of chromophores. 
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Usually a ∆λ = 15 nm in the synchronous fluorescence of BSA is indicative of a tyrosine residue, 
whereas a larger ∆λ = 60 nm is characteristic of tryptophan. Figure 11 shows the synchronous 
fluorescence spectra of BSA with various concentrations of test compounds recorded at ∆λ = 60 
nm. In the synchronous fluorescence spectra of BSA at ∆λ = 60, the addition of the compounds 
to the solution of BSA resulted in a decrease of the fluorescence intensity of BSA at 348 nm for 
the ligand and the complexes indicating that the tryptophan residues were affected by increasing 
the concentration of compounds. The result of the BSA protein binding experiments with our 
compounds has already revealed that the binding of the compounds with BSA is mainly 
hydrophobic in nature. Moreover, the binding strength of the Pd(II) complexes with BSA is 
significantly higher than that of the  ligand, which can be explained by the fact that the 
hydrophobicity of the complex is greater than that of the ligand. So, the strong interaction 
between the Pd(II) complexes and BSA suggested that this compound can easily be stored in 
protein and can be released at  desired target areas. Hence, it will be interesting to study the 
pharmacological properties of Pd(II) complexes. 
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Figure 11. Synchronous spectra of BSA (1µM) in the the ligand (A), complex [PdCl2(L)(PPh3)] 
(B), and complex [PdCl2(L)(AsPh3)] (C) (0 – 100 µM) at a wavelength difference of ∆λ = 60 nm.  
Molecular docking studies 
Molecular docking studies have played a very significant role in delivering a visual 
representation of the binding of the drugs to BSA, which can substantiate the spectroscopic 
results. To ascertain the binding mode of the ligands and complexes with most probable site of 
the bovine serum albumin (BSA), molecular docking studies have been carried out. The protein 
binding interaction model shown in Figure 12 and relative binding energy of the docked 
compounds are showed in Table 6. It has been found that the prime region for interaction of BSA 
with the compounds is in hydrophobic environment of the tryptophan residue. The 
hydrophobicity observed in the molecular docking studies confirmed the effective interaction of 
all the compounds with BSA in static interaction. For the ligand, the atomic interaction is 
between HZ1 of the protein residue LYS431 with H-atom of the quinoline aromatic ring. For the 
complex [PdCl2(L)(PPh3)], the atomic interaction is between oxygen of the protein residue 
LEU112 with the hydrogen atom of the amine. In complex [PdCl2(L)(AsPh3)], the atomic 
interaction is between OE2 of the protein residue GLU125 with the hydrogen atom of the amine. 
The results obtained from molecular docking studies revealed that the interaction between 
complex 1 and BSA is with the highest binding energy dominated by hydrophobic forces. 
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Table 5. Binding energy of the docked compounds. 
Compounds 
Binding_energy 
(Kcal/mol) 
Compound 
Efficiency 
(Kcal/mol) 
Hydrogen 
bond 
formed 
Hydrogen 
bond 
residues 
Distance 
between 
residues (Ao) 
Ligand  -2.57 -0.17 1 LYS431 LYS431(2.6) 
[PdCl2(L)(PPh3)]  -3.8 -0.09 1 LEU112 LEU112(2.2) 
[PdCl2(L)(AsPh3)] -3.5 -0.16 1 GLU125 GLU125(1.8) 
 
 
Ligand 
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Complex [PdCl2(L)(PPh3)]  
 
                                                    Complex [PdCl2(L)(AsPh3)]  
 
Figure 12. Molecular docked model of the compounds.The receptor interactions with 
compounds was represented by magenta and protein residues are cyan and bright orange 
respectively.  
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In vitro cytotoxic activity evaluation  
The positive  results obtained  from the biological studies, namely, DNA binding, BSA binding, 
and BSA docking studies for our compounds prompted  us to test their cytotoxicity against a 
panel of human lung cancer (A-549) and breast cancer (MCF-7) cell lines. Doxorubicin and 
cisplatin were used as a positive control to assess the cytotoxicity of the test compounds. The 
compounds were analyzed by means of cell inhibition expressed as IC50 values and bar chart 
which are shown in Table 7 and in Figure 13. The ligand and the complexes have shown better 
cytotoxic effects on the selected cancer cell lines with lower IC50 values specifying their 
efficiency in killing the cancer cells even at low concentrations. From the results obtained it has 
been found that the palladium complexes [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] and the ligand 
produce inhibition of cell growth even at ˂ 100 µg of concentration on cancer cells indicating 
that our compounds showed significant activity compared to standard anticancer drugs. From the 
two cell lines chosen to examine, complex [PdCl2(L)(PPh3)] showed better cytotoxic specificity 
to human breast cancer cell (MCF-7) than other one. On the other hand, there is no substantial 
difference in the cytotoxic activities when triphenyl phosphine was replaced by triphenyl arsine 
in the complexes. The morphological changes examined by staining method suggested that the 
cell death mechanism was through apoptosis. Overall, the cytotoxicity of the complexes is very 
similar to that of the DNA and protein binding activity, showing a higher potential for 
complex[PdCl2(L)(PPh3)] [40]. 
 
Table 7. The IC50 values of the compounds. 
 
 
 
 
 
 
 
     
                   IC50 values (μM) 
Compound                 A-549         MCF-7 
Ligand                      29 ± 1.1       35 ± 1.5 
[PdCl2(L)(PPh3)]    30 ± 0.9       26 ± 1.4 
[PdCl2(L)(AsPh3)]  31 ± 1.3       29 ± 0.7 
Doxorubicin           15 ± 1.2       16 ± 1.3 
Cisplatin                 25 ± 2.1      18.7 ±  0.1 
 18 
 
 
Figure 13. The IC50 values of compounds are depicted against (A-549) and (MCF-7) cancer cell 
lines. 
Acridine orange /Ethidium bromide (AO/EtBr) staining method 
 Fluorescence microscopy images of (A-549)-(A) and (MCF-7)-(B) cancer cells in the absence of 
compounds (control) and in the presence of the test compounds are shown in (Figure S7). The 
untreated (A-549) and (MCF-7) cancer cells (control-(a), (b), (c)) did not show any significant 
adverse effect compared to the compounds treated with cancer cells (Figure 14-(d), (e), (f)). It 
can be seen  that with the addition of compounds to the cancer cells, the green colour of cells are 
converted into orange/red colour cells which is due to induced apoptosis and the nuclear 
condensation effect on the cells. This indicates that the compounds were significantly inducing 
the apoptosis in selected cancer cells.  
DAPI staining method 
Further, to confirm the nuclear condensation and fragmentation of compounds on selected cancer 
cells, we evaluated the DAPI staining method. Fluorescence microscopy images of Lung and 
breast cancer cells after 24 h stained with DAPI in the absence and presence of compounds are 
shown in (Figure S8). It is seen from the figure that the untreated cells (a, b, c) didn’t show any 
significant change whereas compounds treated cancer cells (d, e, f) showed bright fetches which 
suggest that the condensed chromatins and nuclear fragmentations in the cancer cells. Moreover, 
the bright patches observed for A-549and MCF-7 cell lines are higher for that are treated with 
the test compounds when compared that with untreated ones. Thus, from the results all the 
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studies carried out,we confidently report here that the compounds can be used as potent 
therapeutic agents. 
Conclusion 
The synthesis and characterization of square planar Pd(II) complexes are described. The 
synthesized compounds are characterized by various spectroscopic techniques. The structures of 
the complexes have been confirmed by single crystal X-ray diffraction studies. The coordination 
mode of quinoline observed in [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] is an extremely rare case 
as far as the monodentate coordination behavior of quinoline is concerned. The interaction of 
ligand and complexes with calf thymus CT-DNA, EB displacement and bovine serum albumin 
(BSA) protein was investigated using absorption and fluorescence spectroscopic methods. 
Absorption and emission titration studies revealed that complex 1 interacts with CT-DNA 
through intercalative binding mode and interact to BSA with static quenching mechanism. In 
vitro cytotoxicity results showed that the complex 1 exhibited significant activity against (MCF-
7) cancer cell line. The morphological changes examined by staining method suggested that the 
cell death mechanism was through apoptosis. By changing the substituents on the ligands, the 
anticancer properties of the resulting complexes may be enhanced, and it possible to design 
efficient multifunctional biomolecules in future. 
EXPERIMENTAL SECTION 
Materials and methods. 
All the chemicals were purchased from sigma Aldrich and used as received. Solvents were 
purified and dried according to standard procedures [41]. [PdCl2(PPh3)2] and [PdCl2(AsPh3)2] 
were prepared by literature methods [42-44]. Elemental analyses (CHNS) were performed on 
Vario EL III Elemental analyzer. IR spectra (400-4000 cm-1) were recorded on a JASCO FT-IR 
4100 spectrophotometer with KBr discs. Melting points of the compounds were determined with 
a lab India instrument. The electronic spectra of the compounds were recorded with a Jasco V-
630 spectrophotometer. Emission spectra were measured with Jasco FP 6600 spectrofluorometer. 
DNA binding, Ethidiumbromide(EB) displacement study, protein binding, protein docking and 
cytotoxicity experiments were conducted as per the reported procedures [45-49, 35]. 
Synthesis of the complex, [PdCl2(L)(PPh3)]: 
To a solution of [PdCl2(PPh3)2] (0.100g, 0.1424 mmol) in toluene (20 cm
3), 2-methyl 4-amino 
quinoline, (0.022g, 0.1424 mmol) was added. The mixture was heated under reflux for 6 h during 
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which period a reddish brown precipitate was formed. The reaction mixture was then cooled to 
room temperature, and the solid compound was filtered off. It was washed with petroleum ether 
(60-80 ºC) and dried under vacuum. The complex was then recrystallized from methanol/DMF. 
Reddish brown crystals suitable for X-ray diffraction were obtained. Yield: 78 %. M.p.: 161 ºC. 
Elemental analysis calculated for C28H25Cl2N2PPd (%): Cal: C, 56.26; H, 4.22; N, 4.69. Found 
(%): C, 56.21; H, 4.20; N, 4.62. FT-IR (cm-1) with KBr disk: 3373 (ʋNH2), 1642 (ʋC=N), 1356 
(ʋCH3): UV-visible (Solvent DMSO, nm): 260 (Intra-ligand transition), 328 (Ligand to metal charge 
transfer transition).1H NMR (400 MHz, DMSO-d6, δ, ppm): δ 8.14-8.17 (d, J = 12 Hz, 2H, 
(NH2)), δ 7.30-7.89 (m, Ar-H, 20H), δ 2.89 (s, 3H, (CH3)). 
Synthesis of the complex, [PdCl2(L)(AsPh3)]: 
It was prepared by the same method as described for complex [PdCl2(L)(PPh3)] using 
[PdCl2(AsPh3)2] (0.100g, 0.1266 mmol) and 2-methyl 4-amino quinoline, (0.020g, 0.1266 
mmol). The complex was then recrystallized from methanol/toluene, which yielded yellow 
crystals suitable for X-ray diffraction. Yield: 84 %. M.p.: 156 ºC. Elemental analysis calculated 
for C29H29AsCl2N2OPd: Cal (%): C, 51.69; H, 4.34; N, 4.16. Found (%): C, 51.64; H, 4.29; N, 
4.11. FT-IR (cm-1) with KBr disk: 3391 (ʋNH2), 1638 (ʋC=N), 1359 (ʋCH3): UV-visible (Solvent 
DMSO, nm): 264 (Intra-ligand transition),315 (Ligand to metal charge transfer).1H NMR (500 
MHz, DMSO-d6, δ, ppm): δ 9.48-9.50 (d, J = 10 Hz, 2H, (NH2)),δ 6.73-7.43 (m, Ar-H, 20H), δ 
2.97 (s, 3H, (CH3)). 
Single crystal X-ray diffraction studies 
X-ray diffraction data for [PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] were collected at 100K on a 
Bruker APEX II diffractometer using Mo-Kα radiation (λ = 0.71073 Å). Data collections were 
performed using a CCD area detector from a single crystal mounted on a glass fibre. Absorption 
corrections were based on equivalent reflections using SADABS [50].  The structures were 
solved using Superflip [51] and all of the structures were refined against F2 in SHELXL [52] 
using Olex2 [53]. All of the non-hydrogen atoms were refined anisotropically. While all of the 
hydrogen atoms were located geometrically and refined using a riding model except for the 
hydrogen atoms that are attached to the amine N which were located in the difference map, in the 
case of [PdCl2(L)(PPh3)] restraints were applied to the N-H distance and thermal parameters. 
Crystal structure and refinement data are given in Table 1. Crystallographic data for compounds 
[PdCl2(L)(PPh3)] and [PdCl2(L)(AsPh3)] have been deposited with the Cambridge 
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Crystallographic Data Centre(1498615, 1498616). Copies of the data can be obtained free of 
charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax(+44) 1223 
336033, e-mail: deposit@ccdc.cam.ac.uk]. 
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